Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component

• US 8,017,121 B2
• Filed: 01/09/2001
• Issued: 09/13/2011
• Est. Priority Date: 06/30/1994
• Status: Expired due to Fees

• Current Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG), Tadamistu Kishimoto
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG), Tadamistu Kishimoto
• Inventors: Mihara, Masahiko, Kishimoto, Tadamitsu, Ohsugi, Yoshiyuki, Moriya, Yoichiro
• Primary Examiner(s): Ewoldt; Gerald R
• Application Number:
  US09/756,125
• Publication Number:
  US 20010001663A1
• Time in Patent Office: 3,899 Days
• Field of Search: 424/133.1, 424/141.1, 424/152.1, 424/810, 514/825, 530/387.3, 530/388.1, 530/388.2
• US Class Current: 424/145.1
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

There is provided a synovial cell growth inhibitor, or a pharmaceutical composition for treatment of chronic rheumatoid arthritis based on the synovial cell growth inhibitor.

The pharmaceutical composition for treatment of chronic rheumatoid arthritis or synovial cell growth inhibitor contains an IL-6 antagonist, such as IL-6 antibody or IL-6R antibody, as an effective component.

Claims

1. A method for inhibiting synovial cell growth, comprising administering to a patient in need thereof a pharmaceutical composition comprising reshaped human antibody hPM-1 and a physiologically acceptable carrier.

2. A method of treating chronic rheumatoid arthritis, comprising administering to a patient in need thereof a pharmaceutical composition comprising reshaped human antibody hPM-1 and a physiologically acceptable carrier.

3. The method according to claim 2, wherein the antibody suppresses abnormal growth of synovial cells.